



## Clinical trial results: Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Biological Targeted Treatment SUCCESS B-Trial

### Summary

EudraCT number	2007-001094-29
Trial protocol	DE
Global end of trial date	15 March 2015

### Results information

Result version number	v1 (current)
This version publication date	13 August 2022
First version publication date	13 August 2022
Summary attachment (see zip file)	20190626_SUCCESS-B-trial_Study Report_signed (20190626_SUCCESS-B-trial_Study Report_signed.pdf)

### Trial information

#### Trial identification

Sponsor protocol code	SUCCESS-B-Trial
-----------------------	-----------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00670878
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Klinikum der Universität München
Sponsor organisation address	Maistraße 11, Munich, Germany, 80337
Public contact	Prof. Sommer, Prof. Sommer, Poliklinik + Klinik für Frauenheilkunde + Geburtshilfe, Maistraße 11, Munich, Germany, +49 89 4400 54111, Harald.Sommer@med.uni-muenchen.de
Scientific contact	Prof. Sommer, Prof. Sommer, Poliklinik + Klinik für Frauenheilkunde + Geburtshilfe, Maistraße 11, Munich, Germany, +49 89 4400 54111, Harald.Sommer@med.uni-muenchen.de

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 November 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	15 March 2015
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Das primäre Studienziel ist der Vergleich der rezidivfreien Überlebenszeit nach Randomisierung von Patientinnen, die adjuvant 3 Zyklen Epirubicin-5-Fluorouracil-Cyclophosphamid(FEC)-Chemotherapie, gefolgt von 3 Zyklen Docetaxel (D)-Chemotherapie versus 3 Zyklen Epirubicin-5-Fluorouracil-Cyclophosphamid(FEC)-Chemotherapie, gefolgt von 3 Zyklen Gemcitabine-Docetaxel (DG)-Chemotherapie erhalten.

Protection of trial subjects:

This study was conducted in compliance with Good Clinical Practice (GCP), including the archiving of essential documents.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	10 June 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 793
Worldwide total number of subjects	793
EEA total number of subjects	793

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	637

From 65 to 84 years	156
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Overall, 793 patients were randomized in the SUCCESS B trial. 395 patients were assigned to FEC-Doc chemotherapy and 398 patients were assigned to FEC-DocG chemotherapy.

### Pre-assignment

Screening details:

no pre-screening, no wash-out, no run-in

### Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	FEC-Doc

Arm description:

3 cycles of 5-Fluorouracil 500 mg/m<sup>2</sup> i.v. body surface area and Epirubicin 100 mg/m<sup>2</sup> i.v. and Cyclophosphamide 500 mg/m<sup>2</sup> i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m<sup>2</sup> body surface area i.v. (D), administered on day 1, repeated on day 22

Arm type	Active comparator
Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Infusion

Dosage and administration details:

100 mg/m<sup>2</sup> body surface area i.v.

<b>Arm title</b>	FEC-DocG
------------------	----------

Arm description:

3 cycles of 5-Fluorouracil 500 mg/m<sup>2</sup> i.v. body surface area and Epirubicin 100 mg/m<sup>2</sup> i.v. and Cyclophosphamide 500 mg/m<sup>2</sup> i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m<sup>2</sup> body surface area i.v. (D), and Gemcitabine 1000 mg/m<sup>2</sup> i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m<sup>2</sup> i.v. (30 min infusion) on day 8, repeated on day 22

Arm type	Experimental
Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Infusion

Dosage and administration details:

75 mg/m<sup>2</sup> body surface area i.v.

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Infusion
Routes of administration	Infusion

Dosage and administration details:

1000 mg/m<sup>2</sup> i.v.

<b>Number of subjects in period 1</b>	FEC-Doc	FEC-DocG
Started	395	398
Completed	358	353
Not completed	37	45
Consent withdrawn by subject	13	12
unknown	3	6
Adverse event, non-fatal	15	16
did not receive any chemotherapy	6	9
Protocol deviation	-	2

## Baseline characteristics

### Reporting groups

Reporting group title	FEC-Doc
Reporting group description: 3 cycles of 5-Fluorouracil 500 mg/m <sup>2</sup> i.v. body surface area and Epirubicin 100 mg/m <sup>2</sup> i.v. and Cyclophosphamide 500 mg/m <sup>2</sup> i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m <sup>2</sup> body surface area i.v. (D), administered on day 1, repeated on day 22	
Reporting group title	FEC-DocG
Reporting group description: 3 cycles of 5-Fluorouracil 500 mg/m <sup>2</sup> i.v. body surface area and Epirubicin 100 mg/m <sup>2</sup> i.v. and Cyclophosphamide 500 mg/m <sup>2</sup> i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m <sup>2</sup> body surface area i.v. (D), and Gemcitabine 1000 mg/m <sup>2</sup> i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m <sup>2</sup> i.v. (30 min infusion) on day 8, repeated on day 22	

Reporting group values	FEC-Doc	FEC-DocG	Total
Number of subjects	395	398	793
Age categorical			
Units: Subjects			
Adults (18-64 years)	316	321	637
From 65-84 years	79	77	156
85 years and over	0	0	0
Age continuous			
FEC-Doc Age Mean 55.1 FEC-Doc Age SD 10.3% FEC-DocG Age Mean 54.4 FEC-DocG SD 10%			
Units: years			
arithmetic mean	55.07	54.44	
standard deviation	± 10.292	± 10.003	-
Gender categorical			
Female only - early primary breast cancer patients			
Units: Subjects			
Female	395	398	793

### Subject analysis sets

Subject analysis set title	ITT
Subject analysis set type	Intention-to-treat
Subject analysis set description: This population includes all patients who gave informed consent to take part in this study AND who were randomized into one of the chemotherapy treatment arm (A or B). A total of 793 patients were included into this analysis.	
Subject analysis set title	Safety Population
Subject analysis set type	Safety analysis
Subject analysis set description: defined as all patients who were treated with at least one cycle of FEC chemotherapy (n=778)	

Reporting group values	ITT	Safety Population	
Number of subjects	793	778	
Age categorical			
Units: Subjects			
Adults (18-64 years)	637		
From 65-84 years	156		
85 years and over	0		
Age continuous			
FEC-Doc Age Mean 55.1 FEC-Doc Age SD 10.3% FEC-DocG Age Mean 54.4 FEC-DocG SD 10%			
Units: years			
arithmetic mean	54.75		
standard deviation	± 10.146	±	
Gender categorical			
Female only - early primary breast cancer patients			
Units: Subjects			
Female	793	778	

## End points

### End points reporting groups

Reporting group title	FEC-Doc
Reporting group description: 3 cycles of 5-Fluorouracil 500 mg/m <sup>2</sup> i.v. body surface area and Epirubicin 100 mg/m <sup>2</sup> i.v. and Cyclophosphamide 500 mg/m <sup>2</sup> i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m <sup>2</sup> body surface area i.v. (D), administered on day 1, repeated on day 22	
Reporting group title	FEC-DocG
Reporting group description: 3 cycles of 5-Fluorouracil 500 mg/m <sup>2</sup> i.v. body surface area and Epirubicin 100 mg/m <sup>2</sup> i.v. and Cyclophosphamide 500 mg/m <sup>2</sup> i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m <sup>2</sup> body surface area i.v. (D), and Gemcitabine 1000 mg/m <sup>2</sup> i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m <sup>2</sup> i.v. (30 min infusion) on day 8, repeated on day 22	
Subject analysis set title	ITT
Subject analysis set type	Intention-to-treat
Subject analysis set description: This population includes all patients who gave informed consent to take part in this study AND who were randomized into one of the chemotherapy treatment arm (A or B). A total of 793 patients were included into this analysis.	
Subject analysis set title	Safety Population
Subject analysis set type	Safety analysis
Subject analysis set description: defined as all patients who were treated with at least one cycle of FEC chemotherapy (n=778)	

### Primary: DFS

End point title	DFS
End point description: compare the disease free survival after randomisation in patients treated with 3 cycles of Epirubicin-Fluorouracil-Cyclophosphamide(FEC)-chemotherapy, followed by 3 cycles of Docetaxel(D)-chemotherapy versus 3 cycles of Epirubicin-Fluorouracil-Cyclophosphamide(FEC), followed by 3 cycles of Gemcitabine-Docetaxel(DG)-chemotherapy, both arms followed by biological anti-HER2 treatment respectively	
End point type	Primary
End point timeframe: five years	

End point values	FEC-Doc	FEC-DocG	ITT	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	395	398	793	
Units: event	27	26	53	

### Statistical analyses



<b>Statistical analysis title</b>	Comparison of DFS between the two study arms
Comparison groups	FEC-DocG v FEC-Doc
Number of subjects included in analysis	793
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.97
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.58
upper limit	1.7

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

For the safety evaluation, all adverse events observed within cycles 1 to 6 of the cytostatic treatments were analyzed

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	17

### Reporting groups

Reporting group title	FEC-Doc
-----------------------	---------

Reporting group description:

3 cycles of 5-Fluorouracil 500 mg/m<sup>2</sup> i.v. body surface area and Epirubicin 100 mg/m<sup>2</sup> i.v. and Cyclophosphamide 500 mg/m<sup>2</sup> i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m<sup>2</sup> body surface area i.v. (D), and Gemcitabine 1000 mg/m<sup>2</sup> i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m<sup>2</sup> i.v. (30 min infusion) on day 8, repeated on day 22

Reporting group title	FEC-DocG
-----------------------	----------

Reporting group description:

3 cycles of 5-Fluorouracil 500 mg/m<sup>2</sup> i.v. body surface area and Epirubicin 100 mg/m<sup>2</sup> i.v. and Cyclophosphamide 500 mg/m<sup>2</sup> i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m<sup>2</sup> body surface area i.v. (D), administered on day 1, repeated on day 22

Serious adverse events	FEC-Doc	FEC-DocG	
Total subjects affected by serious adverse events			
subjects affected / exposed	103 / 395 (26.08%)	124 / 398 (31.16%)	
number of deaths (all causes)	14	16	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lymphangiosis carcinomatosa			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to bone			
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Metastases to liver			

subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Metastases to lung			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lymph nodes			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to spine			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Neoplasm progression			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Second primary malignancy			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Uterine cancer			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Circulatory collapse			

subjects affected / exposed	1 / 395 (0.25%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism			
subjects affected / exposed	2 / 395 (0.51%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypertension			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian vein thrombosis			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis superficial			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	5 / 395 (1.27%)	4 / 398 (1.01%)	
occurrences causally related to treatment / all	2 / 5	2 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypotension			

subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Surgical and medical procedures</b>			
<b>Breast operation</b>			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Breast prosthesis implantation</b>			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Breast reconstruction</b>			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hip surgery</b>			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Mammoplasty</b>			
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Mastectomy</b>			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Medical device implantation</b>			
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Medical device removal</b>			

subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian operation			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroidectomy			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest discomfort			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	1 / 395 (0.25%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chills			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disease progression			
subjects affected / exposed	1 / 395 (0.25%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Fatigue			

subjects affected / exposed	2 / 395 (0.51%)	6 / 398 (1.51%)	
occurrences causally related to treatment / all	2 / 2	6 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	4 / 395 (1.01%)	11 / 398 (2.76%)	
occurrences causally related to treatment / all	4 / 5	12 / 14	
deaths causally related to treatment / all	0 / 0	0 / 1	
Impaired healing			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucosal inflammation			
subjects affected / exposed	1 / 395 (0.25%)	5 / 398 (1.26%)	
occurrences causally related to treatment / all	1 / 1	5 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrosis			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Performance status decreased			

subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	9 / 395 (2.28%)	15 / 398 (3.77%)	
occurrences causally related to treatment / all	9 / 9	6 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Breast mass			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Menorrhagia			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Alveolitis			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial hyperreactivity			



subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cough			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	2 / 395 (0.51%)	5 / 398 (1.26%)	
occurrences causally related to treatment / all	1 / 2	5 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infiltration			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary congestion			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			

subjects affected / exposed	1 / 395 (0.25%)	4 / 398 (1.01%)	
occurrences causally related to treatment / all	1 / 1	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary infarction			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheal inflammation			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	1 / 395 (0.25%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fear			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mood altered			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			

Device malfunction			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis in device			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
C-reactive protein increased			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ejection fraction decreased			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Granulocytes abnormal			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutrophil count			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
White blood cell count increased			

subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Fracture			
subjects affected / exposed	3 / 395 (0.76%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural complication			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seroma			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suture related complication			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound complication			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound dehiscence			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			

Angina pectoris			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia supraventricular			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial tachycardia			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular dysfunction			
subjects affected / exposed	2 / 395 (0.51%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	1 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nodal arrhythmia			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			

subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachyarrhythmia			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia paroxysmal			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	1 / 395 (0.25%)	3 / 398 (0.75%)	
occurrences causally related to treatment / all	1 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lethargy			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			

subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle spasticity			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuralgia			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Speech disorder			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia			
subjects affected / exposed	2 / 395 (0.51%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			

subjects affected / exposed	16 / 395 (4.05%)	12 / 398 (3.02%)	
occurrences causally related to treatment / all	17 / 17	13 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukopenia			
subjects affected / exposed	16 / 395 (4.05%)	13 / 398 (3.27%)	
occurrences causally related to treatment / all	19 / 19	18 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenocyst			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	10 / 395 (2.53%)	6 / 398 (1.51%)	
occurrences causally related to treatment / all	10 / 10	6 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	0 / 395 (0.00%)	4 / 398 (1.01%)	
occurrences causally related to treatment / all	0 / 0	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
White blood cell disorder			
subjects affected / exposed	4 / 395 (1.01%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	4 / 4	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
External ear pain			



subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
subjects affected / exposed	0 / 395 (0.00%)	3 / 398 (0.75%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Uveitis			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	2 / 395 (0.51%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	1 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal haemorrhage			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diarrhoea			

subjects affected / exposed	3 / 395 (0.76%)	8 / 398 (2.01%)	
occurrences causally related to treatment / all	3 / 3	7 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	6 / 395 (1.52%)	8 / 398 (2.01%)	
occurrences causally related to treatment / all	6 / 8	8 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	2 / 395 (0.51%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stomatitis			
subjects affected / exposed	2 / 395 (0.51%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Dermatitis allergic			
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema multiforme			

subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin discolouration			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Pollakiuria			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	3 / 395 (0.76%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Urethral caruncle			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Vomiting			
subjects affected / exposed	8 / 395 (2.03%)	8 / 398 (2.01%)	
occurrences causally related to treatment / all	8 / 9	8 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	5 / 395 (1.27%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	1 / 5	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flank pain			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Musculoskeletal pain			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			
subjects affected / exposed	3 / 395 (0.76%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	2 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporosis			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporotic fracture			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast abscess			
subjects affected / exposed	2 / 395 (0.51%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			

subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	2 / 395 (0.51%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis infectious			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	0 / 395 (0.00%)	3 / 398 (0.75%)	
occurrences causally related to treatment / all	0 / 0	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal infection			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			

subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip infection			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastitis			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	1 / 395 (0.25%)	3 / 398 (0.75%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			

subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	FEC-Doc	FEC-DocG	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	387 / 395 (97.97%)	387 / 398 (97.24%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Secondary Malignancy - possibly related to cancer treatment (Specify, ___)			
alternative dictionary used: NCI 3			

subjects affected / exposed occurrences (all)	5 / 395 (1.27%) 5	4 / 398 (1.01%) 4	
Vascular disorders			
Hematoma			
alternative dictionary used: NCI 3			
subjects affected / exposed	3 / 395 (0.76%)	5 / 398 (1.26%)	
occurrences (all)	4	5	
Phlebitis (including superficial thrombosis)			
alternative dictionary used: NCI 3			
subjects affected / exposed	13 / 395 (3.29%)	19 / 398 (4.77%)	
occurrences (all)	14	21	
Thrombosis/embolism (vascular access-related)			
alternative dictionary used: NCI 3			
subjects affected / exposed	5 / 395 (1.27%)	3 / 398 (0.75%)	
occurrences (all)	5	3	
Thrombosis/thrombus/embolism			
alternative dictionary used: NCI 3			
subjects affected / exposed	12 / 395 (3.04%)	16 / 398 (4.02%)	
occurrences (all)	12	16	
Vascular - Other (Specify, __)			
alternative dictionary used: NCI 3			
subjects affected / exposed	0 / 395 (0.00%)	6 / 398 (1.51%)	
occurrences (all)	0	7	
Surgical and medical procedures			
Intra-operative injury - Breast			
alternative dictionary used: NCI 3			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences (all)	0	2	
Intra-operative injury - Oral			
alternative dictionary used: NCI 3			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences (all)	0	1	
Intra-operative Injury - Other (Specify, __)			
alternative dictionary used: NCI 3			



subjects affected / exposed occurrences (all)	3 / 395 (0.76%) 3	3 / 398 (0.75%) 3	
General disorders and administration site conditions			
Constitutional Symptoms - Other (Specify, __)			
alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	23 / 395 (5.82%) 26	38 / 398 (9.55%) 57	
Fatigue (asthenia, lethargy, malaise)			
alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	217 / 395 (54.94%) 403	230 / 398 (57.79%) 422	
Fever			
alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	38 / 395 (9.62%) 48	51 / 398 (12.81%) 67	
Insomnia			
alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	73 / 395 (18.48%) 94	81 / 398 (20.35%) 105	
Odor (patient odor)			
alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	1 / 395 (0.25%) 1	1 / 398 (0.25%) 1	
Rigors/chills			
alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	6 / 395 (1.52%) 7	17 / 398 (4.27%) 28	
Sweating (diaphoresis)			
alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	27 / 395 (6.84%) 31	25 / 398 (6.28%) 28	
Weight gain			
alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	11 / 395 (2.78%) 11	10 / 398 (2.51%) 12	
Weight loss			

alternative dictionary used: NCI 3			
subjects affected / exposed	4 / 395 (1.01%)	11 / 398 (2.76%)	
occurrences (all)	4	11	
Pain - Face			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences (all)	1	0	
Pain - Joint			
alternative dictionary used: NCI 3			
subjects affected / exposed	78 / 395 (19.75%)	76 / 398 (19.10%)	
occurrences (all)	108	109	
Pain - Liver			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences (all)	1	0	
Pain - Oral cavity			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	2 / 398 (0.50%)	
occurrences (all)	1	2	
Pain - Other (Specify, __)			
alternative dictionary used: NCI 3			
subjects affected / exposed	23 / 395 (5.82%)	29 / 398 (7.29%)	
occurrences (all)	28	37	
Pain - Pain NOS			
alternative dictionary used: NCI 3			
subjects affected / exposed	5 / 395 (1.27%)	9 / 398 (2.26%)	
occurrences (all)	5	9	
Flu-like syndrome			
alternative dictionary used: NCI 3			
subjects affected / exposed	7 / 395 (1.77%)	7 / 398 (1.76%)	
occurrences (all)	9	9	
Syndromes - Other (Specify, __)			
alternative dictionary used: NCI 3			
subjects affected / exposed	6 / 395 (1.52%)	6 / 398 (1.51%)	
occurrences (all)	7	7	
Immune system disorders			

Allergic reaction/hypersensitivity (including drug fever) alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	17 / 395 (4.30%) 22	21 / 398 (5.28%) 23	
Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip) alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	6 / 395 (1.52%) 6	11 / 398 (2.76%) 11	
Allergy/Immunology - Other (Specify, __) alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	7 / 395 (1.77%) 7	8 / 398 (2.01%) 8	
Autoimmune reaction alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	0 / 395 (0.00%) 0	1 / 398 (0.25%) 0	
Reproductive system and breast disorders Pain - Breast alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	6 / 395 (1.52%) 6	15 / 398 (3.77%) 17	
Pain - Ovulatory alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	0 / 395 (0.00%) 0	1 / 398 (0.25%) 1	
Pain - Uterus alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	0 / 395 (0.00%) 0	1 / 398 (0.25%) 1	
Breast function/lactation alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	1 / 395 (0.25%) 1	0 / 398 (0.00%) 0	
Breast nipple/areolar deformity alternative dictionary used: NCI 3			

subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences (all)	0	1	
Breast volume/hypoplasia			
alternative dictionary used: NCI 3			
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)	
occurrences (all)	0	2	
Irregular menses (change from baseline)			
alternative dictionary used: NCI 3			
subjects affected / exposed	2 / 395 (0.51%)	3 / 398 (0.75%)	
occurrences (all)	2	4	
Libido			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences (all)	1	1	
Sexual/Reproductive Function - Other (Specify, __)			
alternative dictionary used: NCI 3			
subjects affected / exposed	5 / 395 (1.27%)	7 / 398 (1.76%)	
occurrences (all)	5	10	
Vaginal discharge (non-infectious)			
alternative dictionary used: NCI 3			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences (all)	0	1	
Vaginal dryness			
alternative dictionary used: NCI 3			
subjects affected / exposed	3 / 395 (0.76%)	7 / 398 (1.76%)	
occurrences (all)	3	8	
Vaginal mucositis			
alternative dictionary used: NCI 3			
subjects affected / exposed	2 / 395 (0.51%)	3 / 398 (0.75%)	
occurrences (all)	2	3	
Vaginitis (not due to infection)			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	2 / 398 (0.50%)	
occurrences (all)	1	2	
Respiratory, thoracic and mediastinal disorders			

Pain - Larynx		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)
occurrences (all)	0	2
Pain - Pleura		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)
occurrences (all)	0	2
Pain - Throat/pharynx/larynx		
alternative dictionary used: NCI 3		
subjects affected / exposed	10 / 395 (2.53%)	15 / 398 (3.77%)
occurrences (all)	12	15
Bronchospasm, wheezing		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Cough		
alternative dictionary used: NCI 3		
subjects affected / exposed	32 / 395 (8.10%)	46 / 398 (11.56%)
occurrences (all)	33	53
Dyspnea (shortness of breath)		
alternative dictionary used: NCI 3		
subjects affected / exposed	62 / 395 (15.70%)	77 / 398 (19.35%)
occurrences (all)	78	97
Nasal cavity/paranasal sinus reactions		
alternative dictionary used: NCI 3		
subjects affected / exposed	10 / 395 (2.53%)	2 / 398 (0.50%)
occurrences (all)	10	2
Obstruction/stenosis of airway - Bronchus		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	2
Pleural effusion (non-malignant)		
alternative dictionary used: NCI 3		

subjects affected / exposed occurrences (all)	1 / 395 (0.25%) 1	4 / 398 (1.01%) 4	
Pneumonitis/pulmonary infiltrates alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	3 / 395 (0.76%) 3	7 / 398 (1.76%) 7	
Pneumothorax alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	0 / 395 (0.00%) 0	1 / 398 (0.25%) 1	
Pulmonary/Upper Respiratory - Other (Specify, __) alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	6 / 395 (1.52%) 7	12 / 398 (3.02%) 15	
Voice changes/dysarthria (e.g., hoarseness, loss or alteration in voice, laryngitis) alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	3 / 395 (0.76%) 3	3 / 398 (0.75%) 3	
Investigations			
Alkaline phosphatase alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	25 / 395 (6.33%) 28	30 / 398 (7.54%) 46	
ALT, SGPT (serum glutamic pyruvic transaminase) alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	101 / 395 (25.57%) 166	173 / 398 (43.47%) 338	
AST, SGOT (serum glutamic oxaloacetic transaminase) alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	82 / 395 (20.76%) 125	137 / 398 (34.42%) 226	
Bilirubin (hyperbilirubinemia) alternative dictionary used: NCI 3			

subjects affected / exposed	2 / 395 (0.51%)	4 / 398 (1.01%)
occurrences (all)	2	8
Calcium, serum-high (hypercalcemia) alternative dictionary used: NCI 3		
subjects affected / exposed	2 / 395 (0.51%)	3 / 398 (0.75%)
occurrences (all)	2	3
Calcium, serum-low (hypocalcemia) alternative dictionary used: NCI 3		
subjects affected / exposed	2 / 395 (0.51%)	4 / 398 (1.01%)
occurrences (all)	2	5
Cholesterol, serum-high (hypercholesteremia) alternative dictionary used: NCI 3		
subjects affected / exposed	3 / 395 (0.76%)	1 / 398 (0.25%)
occurrences (all)	4	1
CPK (creatine phosphokinase) alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Creatinine alternative dictionary used: NCI 3		
subjects affected / exposed	17 / 395 (4.30%)	8 / 398 (2.01%)
occurrences (all)	20	12
GGT (gamma-Glutamyl transpeptidase) alternative dictionary used: NCI 3		
subjects affected / exposed	90 / 395 (22.78%)	119 / 398 (29.90%)
occurrences (all)	135	210
Glomerular filtration rate alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	3 / 398 (0.75%)
occurrences (all)	0	3
Glucose, serum-high (hyperglycemia) alternative dictionary used: NCI 3		
subjects affected / exposed	4 / 395 (1.01%)	6 / 398 (1.51%)
occurrences (all)	8	16

Lipase		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	1
Magnesium, serum-low (hypomagnesemia)		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Metabolic/Laboratory - Other (Specify, __)		
alternative dictionary used: NCI 3		
subjects affected / exposed	15 / 395 (3.80%)	27 / 398 (6.78%)
occurrences (all)	18	32
Phosphate, serum-low (hypophosphatemia)		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Potassium, serum-high (hyperkalemia)		
alternative dictionary used: NCI 3		
subjects affected / exposed	13 / 395 (3.29%)	12 / 398 (3.02%)
occurrences (all)	25	14
Potassium, serum-low (hypokalemia)		
alternative dictionary used: NCI 3		
subjects affected / exposed	13 / 395 (3.29%)	21 / 398 (5.28%)
occurrences (all)	13	25
Proteinuria		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Sodium, serum-high (hypernatremia)		
alternative dictionary used: NCI 3		
subjects affected / exposed	3 / 395 (0.76%)	2 / 398 (0.50%)
occurrences (all)	5	2
Sodium, serum-low (hyponatremia)		
alternative dictionary used: NCI 3		



<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 395 (1.01%)</p> <p>7</p>	<p>12 / 398 (3.02%)</p> <p>15</p>	
<p>Triglyceride, serum-high (hypertriglyceridemia)</p> <p>alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 395 (0.25%)</p> <p>1</p>	<p>1 / 398 (0.25%)</p> <p>1</p>	
<p>Uric acid, serum-high (hyperuricemia)</p> <p>alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 395 (1.01%)</p> <p>6</p>	<p>8 / 398 (2.01%)</p> <p>9</p>	
<p>Cardiac disorders</p> <p>Cardiac Arrhythmia - Other (Specify, ___)</p> <p>alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 395 (1.01%)</p> <p>4</p>	<p>2 / 398 (0.50%)</p> <p>2</p>	
<p>Palpitations</p> <p>alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>10 / 395 (2.53%)</p> <p>8</p>	<p>9 / 398 (2.26%)</p> <p>7</p>	
<p>Supraventricular and nodal arrhythmia - Atrial fibrillation</p> <p>alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 395 (0.25%)</p> <p>1</p>	<p>0 / 398 (0.00%)</p> <p>0</p>	
<p>Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia</p> <p>alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 395 (0.51%)</p> <p>3</p>	<p>1 / 398 (0.25%)</p> <p>1</p>	
<p>Supraventricular and nodal arrhythmia - Nodal/Junctional</p> <p>alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 395 (0.00%)</p> <p>0</p>	<p>1 / 398 (0.25%)</p> <p>2</p>	
<p>Supraventricular and nodal arrhythmia - Sinus arrhythmia</p>			

alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Supraventricular and nodal arrhythmia - Sinus bradycardia		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Supraventricular and nodal arrhythmia - Sinus tachycardia		
alternative dictionary used: NCI 3		
subjects affected / exposed	9 / 395 (2.28%)	9 / 398 (2.26%)
occurrences (all)	9	10
Supraventricular and nodal arrhythmia - Supraventricular tachycardia		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)
occurrences (all)	0	2
Vasovagal episode		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	1
Ventricular arrhythmia - Idioventricular rhythm		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Ventricular arrhythmia - Ventricular flutter		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	2	0
Ventricular arrhythmia - Ventricular tachycardia		
alternative dictionary used: NCI 3		
subjects affected / exposed	8 / 395 (2.03%)	9 / 398 (2.26%)
occurrences (all)	9	9
Cardiac General - Other (Specify, __)		
alternative dictionary used: NCI 3		

subjects affected / exposed	6 / 395 (1.52%)	11 / 398 (2.76%)
occurrences (all)	7	12
Cardiac ischemia/infarction alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Hypertension alternative dictionary used: NCI 3		
subjects affected / exposed	13 / 395 (3.29%)	16 / 398 (4.02%)
occurrences (all)	14	19
Hypotension alternative dictionary used: NCI 3		
subjects affected / exposed	11 / 395 (2.78%)	17 / 398 (4.27%)
occurrences (all)	15	19
Left ventricular diastolic dysfunction alternative dictionary used: NCI 3		
subjects affected / exposed	3 / 395 (0.76%)	1 / 398 (0.25%)
occurrences (all)	3	1
Left ventricular systolic dysfunction alternative dictionary used: NCI 3		
subjects affected / exposed	12 / 395 (3.04%)	3 / 398 (0.75%)
occurrences (all)	18	3
Pericardial effusion (non-malignant) alternative dictionary used: NCI 3		
subjects affected / exposed	3 / 395 (0.76%)	2 / 398 (0.50%)
occurrences (all)	3	2
Restrictive cardiomyopathy alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	1
Pain - Cardiac/heart alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	1
Pain - Chest wall alternative dictionary used: NCI 3		

subjects affected / exposed occurrences (all)	2 / 395 (0.51%) 2	4 / 398 (1.01%) 4	
Pain - Chest/thorax NOS alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	3 / 395 (0.76%) 4	9 / 398 (2.26%) 9	
Nervous system disorders			
Ataxia (incoordination) alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	0 / 395 (0.00%) 0	1 / 398 (0.25%) 1	
Cognitive disturbance alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	5 / 395 (1.27%) 5	2 / 398 (0.50%) 2	
Confusion alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	0 / 395 (0.00%) 0	1 / 398 (0.25%) 1	
Dizziness alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	43 / 395 (10.89%) 64	48 / 398 (12.06%) 66	
Extrapyramidal/involuntary movement/restlessness alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	2 / 395 (0.51%) 2	3 / 398 (0.75%) 4	
Memory impairment alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	6 / 395 (1.52%) 6	9 / 398 (2.26%) 9	
Mental status alternative dictionary used: NCI 3			
subjects affected / exposed occurrences (all)	0 / 395 (0.00%) 0	1 / 398 (0.25%) 1	
Mood alteration - Agitation			

alternative dictionary used: NCI 3		
subjects affected / exposed	5 / 395 (1.27%)	4 / 398 (1.01%)
occurrences (all)	5	4
Mood alteration - Anxiety		
alternative dictionary used: NCI 3		
subjects affected / exposed	5 / 395 (1.27%)	5 / 398 (1.26%)
occurrences (all)	5	6
Mood alteration - Depression		
alternative dictionary used: NCI 3		
subjects affected / exposed	31 / 395 (7.85%)	35 / 398 (8.79%)
occurrences (all)	36	55
Neurology - Other (Specify, __)		
alternative dictionary used: NCI 3		
subjects affected / exposed	13 / 395 (3.29%)	17 / 398 (4.27%)
occurrences (all)	15	21
Neuropathy: cranial - CN I Smell		
alternative dictionary used: NCI 3		
subjects affected / exposed	2 / 395 (0.51%)	0 / 398 (0.00%)
occurrences (all)	2	0
Neuropathy: cranial - CN IX Motor-pharynx; Sensory-ear, pharynx, tongue		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Neuropathy: cranial - CN V Motor-jaw muscles; Sensory-facial		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Neuropathy: cranial - CN VII Motor-face; Sensory-taste		
alternative dictionary used: NCI 3		
subjects affected / exposed	3 / 395 (0.76%)	2 / 398 (0.50%)
occurrences (all)	3	2
Neuropathy: motor		
alternative dictionary used: NCI 3		

subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences (all)	1	0	
Neuropathy: sensory			
alternative dictionary used: NCI 3			
subjects affected / exposed	155 / 395 (39.24%)	132 / 398 (33.17%)	
occurrences (all)	202	175	
Personality/behavioral			
alternative dictionary used: NCI 3			
subjects affected / exposed	3 / 395 (0.76%)	0 / 398 (0.00%)	
occurrences (all)	3	0	
Seizure			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)	
occurrences (all)	1	1	
Speech impairment (e.g., dysphasia or aphasia)			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences (all)	1	0	
Syncope (fainting)			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	6 / 398 (1.51%)	
occurrences (all)	1	7	
Tremor			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	2 / 398 (0.50%)	
occurrences (all)	1	2	
Pain - Head/headache			
alternative dictionary used: NCI 3			
subjects affected / exposed	53 / 395 (13.42%)	77 / 398 (19.35%)	
occurrences (all)	75	113	
Pain - Neuralgia/peripheral nerve			
alternative dictionary used: NCI 3			
subjects affected / exposed	12 / 395 (3.04%)	5 / 398 (1.26%)	
occurrences (all)	14	5	
Blood and lymphatic system disorders			

Blood/Bone Marrow - Other (Specify, ___)		
alternative dictionary used: NCI 3		
subjects affected / exposed	41 / 395 (10.38%)	63 / 398 (15.83%)
occurrences (all)	105	188
Haptoglobin		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Hemoglobin		
alternative dictionary used: NCI 3		
subjects affected / exposed	223 / 395 (56.46%)	279 / 398 (70.10%)
occurrences (all)	531	683
Leukocytes (total WBC)		
alternative dictionary used: NCI 3		
subjects affected / exposed	291 / 395 (73.67%)	316 / 398 (79.40%)
occurrences (all)	1451	1519
Lymphopenia		
alternative dictionary used: NCI 3		
subjects affected / exposed	15 / 395 (3.80%)	11 / 398 (2.76%)
occurrences (all)	28	20
Neutrophils/granulocytes (ANC/AGC)		
alternative dictionary used: NCI 3		
subjects affected / exposed	182 / 395 (46.08%)	198 / 398 (49.75%)
occurrences (all)	658	643
Platelets		
alternative dictionary used: NCI 3		
subjects affected / exposed	65 / 395 (16.46%)	88 / 398 (22.11%)
occurrences (all)	105	181
Splenic function		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Coagulation - Other (Specify, ___)		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0

Fibrinogen		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
PTT (Partial Thromboplastin Time)		
alternative dictionary used: NCI 3		
subjects affected / exposed	3 / 395 (0.76%)	4 / 398 (1.01%)
occurrences (all)	3	4
Thrombotic microangiopathy		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Dermal change lymphedema, phlebolymphe <sup>1</sup> edema		
alternative dictionary used: NCI 3		
subjects affected / exposed	7 / 395 (1.77%)	3 / 398 (0.75%)
occurrences (all)	8	3
Edema: head and neck		
alternative dictionary used: NCI 3		
subjects affected / exposed	4 / 395 (1.01%)	4 / 398 (1.01%)
occurrences (all)	4	5
Edema: limb		
alternative dictionary used: NCI 3		
subjects affected / exposed	77 / 395 (19.49%)	57 / 398 (14.32%)
occurrences (all)	103	78
Edema: trunk/genital		
alternative dictionary used: NCI 3		
subjects affected / exposed	2 / 395 (0.51%)	1 / 398 (0.25%)
occurrences (all)	2	1
Edema: viscera		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	3 / 398 (0.75%)
occurrences (all)	2	3
Lymphatics - Other (Specify, __)		
alternative dictionary used: NCI 3		
subjects affected / exposed	12 / 395 (3.04%)	18 / 398 (4.52%)
occurrences (all)	12	20



Lymphedema-related fibrosis alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	4 / 395 (1.01%) 4	1 / 398 (0.25%) 1	
Pain - Lymph node alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	1 / 395 (0.25%) 1	1 / 398 (0.25%) 1	
Ear and labyrinth disorders Auditory/Ear - Other (Specify, __) alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	1 / 395 (0.25%) 0	0 / 398 (0.00%) 0	
Hearing: patients without baseline audiogram and not enrolled in a monitoring program alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	1 / 395 (0.25%) 1	3 / 398 (0.75%) 3	
Otitis, middle ear (non-infectious) alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	3 / 395 (0.76%) 3	1 / 398 (0.25%) 1	
Tinnitus alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	1 / 395 (0.25%) 1	1 / 398 (0.25%) 1	
Pain - External ear alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	1 / 395 (0.25%) 1	1 / 398 (0.25%) 1	
Eye disorders Cataract alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	2 / 395 (0.51%) 3	0 / 398 (0.00%) 0	
Dry eye syndrome alternative dictionary used: NCI 3			

subjects affected / exposed	23 / 395 (5.82%)	23 / 398 (5.78%)
occurrences (all)	28	28
Eyelid dysfunction		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)
occurrences (all)	0	2
Glaucoma		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Keratitis (corneal inflammation/corneal ulceration)		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	1
Ocular surface disease		
alternative dictionary used: NCI 3		
subjects affected / exposed	9 / 395 (2.28%)	11 / 398 (2.76%)
occurrences (all)	11	11
Ocular/Visual - Other (Specify, __)		
alternative dictionary used: NCI 3		
subjects affected / exposed	13 / 395 (3.29%)	15 / 398 (3.77%)
occurrences (all)	15	17
Optic disc edema		
alternative dictionary used: NCI 3		
subjects affected / exposed	4 / 395 (1.01%)	5 / 398 (1.26%)
occurrences (all)	5	9
Retinopathy		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Uveitis		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Vision-blurred vision		
alternative dictionary used: NCI 3		

subjects affected / exposed occurrences (all)	4 / 395 (1.01%) 4	4 / 398 (1.01%) 4	
Watery eye (epiphora, tearing) subjects affected / exposed occurrences (all)	41 / 395 (10.38%) 44	26 / 398 (6.53%) 28	
Pain - Eye alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	2 / 395 (0.51%) 2	4 / 398 (1.01%) 4	
Gastrointestinal disorders			
Anorexia alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	35 / 395 (8.86%) 51	26 / 398 (6.53%) 33	
Ascites (non-malignant) alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	1 / 395 (0.25%) 1	0 / 398 (0.00%) 0	
Colitis alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	0 / 395 (0.00%) 0	2 / 398 (0.50%) 2	
Constipation alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	118 / 395 (29.87%) 181	106 / 398 (26.63%) 160	
Dehydration alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	3 / 395 (0.76%) 3	2 / 398 (0.50%) 2	
Dental: periodontal disease alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	2 / 395 (0.51%) 3	1 / 398 (0.25%) 1	
Dental: teeth alternative dictionary used: NCI 3			

subjects affected / exposed	2 / 395 (0.51%)	3 / 398 (0.75%)
occurrences (all)	2	3
Dental: teeth development		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Diarrhea		
alternative dictionary used: NCI 3		
subjects affected / exposed	121 / 395 (30.63%)	144 / 398 (36.18%)
occurrences (all)	170	208
Distension/bloating, abdominal		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	4 / 398 (1.01%)
occurrences (all)	1	4
Dry mouth/salivary gland (xerostomia)		
alternative dictionary used: NCI 3		
subjects affected / exposed	36 / 395 (9.11%)	30 / 398 (7.54%)
occurrences (all)	44	35
Dysphagia (difficulty swallowing)		
alternative dictionary used: NCI 3		
subjects affected / exposed	9 / 395 (2.28%)	18 / 398 (4.52%)
occurrences (all)	10	24
Enteritis (inflammation of the small bowel)		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	1
Esophagitis		
alternative dictionary used: NCI 3		
subjects affected / exposed	3 / 395 (0.76%)	7 / 398 (1.76%)
occurrences (all)	6	9
Fistula, GI - Anus		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Flatulence		

alternative dictionary used: NCI 3		
subjects affected / exposed	2 / 395 (0.51%)	9 / 398 (2.26%)
occurrences (all)	2	11
Gastritis (including bile reflux gastritis)		
alternative dictionary used: NCI 3		
subjects affected / exposed	10 / 395 (2.53%)	8 / 398 (2.01%)
occurrences (all)	11	8
Gastrointestinal - Other (Specify, ___)		
alternative dictionary used: NCI 3		
subjects affected / exposed	16 / 395 (4.05%)	17 / 398 (4.27%)
occurrences (all)	27	26
Heartburn/dyspepsia		
alternative dictionary used: NCI 3		
subjects affected / exposed	40 / 395 (10.13%)	35 / 398 (8.79%)
occurrences (all)	48	45
Hemorrhoids		
alternative dictionary used: NCI 3		
subjects affected / exposed	4 / 395 (1.01%)	3 / 398 (0.75%)
occurrences (all)	4	3
Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation)		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Incontinence, anal		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Leak (including anastomotic), GI - Biliary tree		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Leak (including anastomotic), GI - Pancreas		
alternative dictionary used: NCI 3		

subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Mucositis/stomatitis (clinical exam) - Anus		
alternative dictionary used: NCI 3		
subjects affected / exposed	3 / 395 (0.76%)	1 / 398 (0.25%)
occurrences (all)	3	1
Mucositis/stomatitis (clinical exam) - Esophagus		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	1
Mucositis/stomatitis (clinical exam) - Larynx		
alternative dictionary used: NCI 3		
subjects affected / exposed	5 / 395 (1.27%)	4 / 398 (1.01%)
occurrences (all)	8	4
Mucositis/stomatitis (clinical exam) - Oral cavity		
alternative dictionary used: NCI 3		
subjects affected / exposed	128 / 395 (32.41%)	137 / 398 (34.42%)
occurrences (all)	182	200
Mucositis/stomatitis (clinical exam) - Pharynx		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	3 / 398 (0.75%)
occurrences (all)	1	3
Mucositis/stomatitis (clinical exam) - Small bowel		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	2	0
Mucositis/stomatitis (clinical exam) - Stomach		
alternative dictionary used: NCI 3		
subjects affected / exposed	15 / 395 (3.80%)	11 / 398 (2.76%)
occurrences (all)	27	12
Mucositis/stomatitis (clinical exam) - Trachea		
alternative dictionary used: NCI 3		

subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Mucositis/stomatitis (functional/symptomatic) - Anus alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Mucositis/stomatitis (functional/symptomatic) - Esophagus alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	2 / 398 (0.50%)
occurrences (all)	1	3
Mucositis/stomatitis (functional/symptomatic) - Larynx alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	2 / 398 (0.50%)
occurrences (all)	1	3
Mucositis/stomatitis (functional/symptomatic) - Oral cavity alternative dictionary used: NCI 3		
subjects affected / exposed	82 / 395 (20.76%)	97 / 398 (24.37%)
occurrences (all)	122	128
Mucositis/stomatitis (functional/symptomatic) - Pharynx alternative dictionary used: NCI 3		
subjects affected / exposed	7 / 395 (1.77%)	6 / 398 (1.51%)
occurrences (all)	8	6
Mucositis/stomatitis (functional/symptomatic) - Small bowel alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Mucositis/stomatitis (functional/symptomatic) - Stomach alternative dictionary used: NCI 3		
subjects affected / exposed	16 / 395 (4.05%)	16 / 398 (4.02%)
occurrences (all)	19	33
Mucositis/stomatitis (functional/symptomatic) - Trachea		

alternative dictionary used: NCI 3		
subjects affected / exposed	5 / 395 (1.27%)	6 / 398 (1.51%)
occurrences (all)	6	7
Nausea		
alternative dictionary used: NCI 3		
subjects affected / exposed	228 / 395 (57.72%)	249 / 398 (62.56%)
occurrences (all)	436	501
Obstruction, GI - Colon		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	4 / 398 (1.01%)
occurrences (all)	1	6
Obstruction, GI - Rectum		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)
occurrences (all)	0	2
Perforation, GI - Appendix		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	1
Proctitis		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Salivary gland changes/saliva		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	2 / 398 (0.50%)
occurrences (all)	1	3
Taste alteration (dysgeusia)		
alternative dictionary used: NCI 3		
subjects affected / exposed	65 / 395 (16.46%)	68 / 398 (17.09%)
occurrences (all)	89	91
Vomiting		
alternative dictionary used: NCI 3		
subjects affected / exposed	101 / 395 (25.57%)	106 / 398 (26.63%)
occurrences (all)	136	155
Hemorrhage, GI - Anus		



alternative dictionary used: NCI 3		
subjects affected / exposed	3 / 395 (0.76%)	0 / 398 (0.00%)
occurrences (all)	4	0
Hemorrhage, GI - Oral cavity		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	3 / 398 (0.75%)
occurrences (all)	1	4
Hemorrhage, GI - Rectum		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	1
Hemorrhage, GI - Upper GI NOS		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Hemorrhage, GI - Varices (rectal)		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Hemorrhage, GU - Ovary		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Hemorrhage, GU - Urinary NOS		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Hemorrhage, GU - Uterus		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	2
Hemorrhage, GU - Vagina		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	2	1
Hemorrhage, pulmonary/upper respiratory - Nose		

alternative dictionary used: NCI 3		
subjects affected / exposed	16 / 395 (4.05%)	18 / 398 (4.52%)
occurrences (all)	22	23
Hemorrhage/Bleeding - Other (Specify, __)		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	3 / 398 (0.75%)
occurrences (all)	2	3
Petechiae/purpura (hemorrhage/bleeding into skin or mucosa)		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Pain - Abdomen NOS		
alternative dictionary used: NCI 3		
subjects affected / exposed	13 / 395 (3.29%)	19 / 398 (4.77%)
occurrences (all)	17	22
Pain - Anus		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)
occurrences (all)	1	0
Pain - Bladder		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Pain - Dental/teeth/peridontal		
alternative dictionary used: NCI 3		
subjects affected / exposed	5 / 395 (1.27%)	6 / 398 (1.51%)
occurrences (all)	5	6
Pain - Esophagus		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	4 / 398 (1.01%)
occurrences (all)	0	4
Pain - Intestine		
alternative dictionary used: NCI 3		
subjects affected / exposed	3 / 395 (0.76%)	1 / 398 (0.25%)
occurrences (all)	4	2

Pain - Stomach alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	15 / 395 (3.80%) 21	33 / 398 (8.29%) 43	
Hepatobiliary disorders Hepatobiliary/Pancreas - Other (Specify, __) alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)  Liver dysfunction/failure (clinical) alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)  Pancreatitis alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)  Pain - Gallbladder alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	2 / 395 (0.51%) 2  2 / 395 (0.51%) 2  2 / 395 (0.51%) 2  0 / 395 (0.00%) 0	1 / 398 (0.25%) 1  1 / 398 (0.25%) 1  1 / 398 (0.25%) 1  1 / 398 (0.25%) 1	
Skin and subcutaneous tissue disorders Atrophy alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)  Bruising alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)  Burn alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)  Cheilitis alternative dictionary used: NCI 3	0 / 395 (0.00%) 0  1 / 395 (0.25%) 1  2 / 395 (0.51%) 3	1 / 398 (0.25%) 1  0 / 398 (0.00%) 0  2 / 398 (0.50%) 2	

subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	2	1
Dermatology/Skin - Other (Specify, ___)		
alternative dictionary used: NCI 3		
subjects affected / exposed	38 / 395 (9.62%)	43 / 398 (10.80%)
occurrences (all)	56	61
Dry skin		
alternative dictionary used: NCI 3		
subjects affected / exposed	47 / 395 (11.90%)	51 / 398 (12.81%)
occurrences (all)	54	67
Flushing		
alternative dictionary used: NCI 3		
subjects affected / exposed	23 / 395 (5.82%)	24 / 398 (6.03%)
occurrences (all)	33	34
Hair loss/alopecia (scalp or body)		
alternative dictionary used: NCI 3		
subjects affected / exposed	307 / 395 (77.72%)	285 / 398 (71.61%)
occurrences (all)	343	317
Hyperpigmentation		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	3 / 398 (0.75%)
occurrences (all)	1	4
Hypopigmentation		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Induration/fibrosis (skin and subcutaneous tissue)		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	5 / 398 (1.26%)
occurrences (all)	1	5
Injection site reaction/extravasation changes		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	3 / 398 (0.75%)
occurrences (all)	0	3
Nail changes		

alternative dictionary used: NCI 3		
subjects affected / exposed	104 / 395 (26.33%)	84 / 398 (21.11%)
occurrences (all)	113	98
Pruritus/itching		
alternative dictionary used: NCI 3		
subjects affected / exposed	10 / 395 (2.53%)	16 / 398 (4.02%)
occurrences (all)	10	22
Rash/desquamation		
alternative dictionary used: NCI 3		
subjects affected / exposed	14 / 395 (3.54%)	11 / 398 (2.76%)
occurrences (all)	14	13
Rash: acne/acneiform		
alternative dictionary used: NCI 3		
subjects affected / exposed	10 / 395 (2.53%)	17 / 398 (4.27%)
occurrences (all)	11	19
Rash: dermatitis associated with radiation - Chemoradiation		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	1
Rash: dermatitis associated with radiation - Radiation		
alternative dictionary used: NCI 3		
subjects affected / exposed	3 / 395 (0.76%)	5 / 398 (1.26%)
occurrences (all)	3	5
Rash: erythema multiforme		
alternative dictionary used: NCI 3		
subjects affected / exposed	5 / 395 (1.27%)	4 / 398 (1.01%)
occurrences (all)	5	4
Rash: hand-foot skin reaction		
alternative dictionary used: NCI 3		
subjects affected / exposed	57 / 395 (14.43%)	30 / 398 (7.54%)
occurrences (all)	65	35
Skin breakdown/decubitus ulcer		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)
occurrences (all)	0	2

Striae			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences (all)	1	0	
Telangiectasia			
alternative dictionary used: NCI 3			
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)	
occurrences (all)	0	1	
Ulceration			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences (all)	1	2	
Urticaria (hives, welts, wheals)			
subjects affected / exposed	1 / 395 (0.25%)	3 / 398 (0.75%)	
occurrences (all)	1	3	
Wound complication, non-infectious			
alternative dictionary used: NCI 3			
subjects affected / exposed	5 / 395 (1.27%)	3 / 398 (0.75%)	
occurrences (all)	6	3	
Pain - Skin			
alternative dictionary used: NCI 3			
subjects affected / exposed	0 / 395 (0.00%)	2 / 398 (0.50%)	
occurrences (all)	0	2	
Renal and urinary disorders			
Pain - Kidney			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	3 / 398 (0.75%)	
occurrences (all)	1	3	
Bladder spasms			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences (all)	1	0	
Cystitis			
alternative dictionary used: NCI 3			
subjects affected / exposed	12 / 395 (3.04%)	25 / 398 (6.28%)	
occurrences (all)	14	33	
Incontinence, urinary			

alternative dictionary used: NCI 3			
subjects affected / exposed	2 / 395 (0.51%)	3 / 398 (0.75%)	
occurrences (all)	2	3	
Renal failure			
alternative dictionary used: NCI 3			
subjects affected / exposed	2 / 395 (0.51%)	0 / 398 (0.00%)	
occurrences (all)	2	0	
Renal/Genitourinary - Other (Specify, __)			
alternative dictionary used: NCI 3			
subjects affected / exposed	5 / 395 (1.27%)	7 / 398 (1.76%)	
occurrences (all)	5	8	
Urinary frequency/urgency			
alternative dictionary used: NCI 3			
subjects affected / exposed	11 / 395 (2.78%)	7 / 398 (1.76%)	
occurrences (all)	11	7	
Urinary retention (including neurogenic bladder)			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences (all)	1	0	
Endocrine disorders			
Endocrine - Other (Specify, __)			
alternative dictionary used: NCI 3			
subjects affected / exposed	2 / 395 (0.51%)	3 / 398 (0.75%)	
occurrences (all)	2	3	
Hot flashes/flushes			
alternative dictionary used: NCI 3			
subjects affected / exposed	67 / 395 (16.96%)	67 / 398 (16.83%)	
occurrences (all)	98	92	
Pancreatic endocrine: glucose intolerance			
alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences (all)	1	0	
Parathyroid function, low (hypoparathyroidism)			
alternative dictionary used: NCI 3			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Thyroid function, high (hyperthyroidism, thyrotoxicosis) alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Thyroid function, low (hypothyroidism) alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Growth and Development - Other (Specify, __) alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 395 (0.00%)</p> <p>0</p> <p>1 / 395 (0.25%)</p> <p>1</p> <p>3 / 395 (0.76%)</p> <p>3</p> <p>1 / 395 (0.25%)</p> <p>1</p>	<p>1 / 398 (0.25%)</p> <p>1</p> <p>2 / 398 (0.50%)</p> <p>2</p> <p>2 / 398 (0.50%)</p> <p>2</p> <p>0 / 398 (0.00%)</p> <p>0</p>	
<p>Musculoskeletal and connective tissue disorders</p> <p>Arthritis (non-septic) alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Bone: spine-scoliosis alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Cervical spine-range of motion alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Extremity-lower (gait/walking) alternative dictionary used: NCI 3</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Extremity-upper (function) alternative dictionary used: NCI 3</p>	<p>4 / 395 (1.01%)</p> <p>4</p> <p>0 / 395 (0.00%)</p> <p>0</p> <p>0 / 395 (0.00%)</p> <p>0</p> <p>0 / 395 (0.00%)</p> <p>0</p>	<p>6 / 398 (1.51%)</p> <p>13</p> <p>1 / 398 (0.25%)</p> <p>1</p> <p>1 / 398 (0.25%)</p> <p>1</p> <p>1 / 398 (0.25%)</p> <p>1</p>	



subjects affected / exposed	2 / 395 (0.51%)	1 / 398 (0.25%)
occurrences (all)	2	1
Fracture		
alternative dictionary used: NCI 3		
subjects affected / exposed	5 / 395 (1.27%)	5 / 398 (1.26%)
occurrences (all)	5	5
Joint-function		
alternative dictionary used: NCI 3		
subjects affected / exposed	3 / 395 (0.76%)	2 / 398 (0.50%)
occurrences (all)	3	2
Lumbar spine-range of motion		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Muscle weakness, generalized or specific area (not due to neuropathy)		
alternative dictionary used: NCI 3		
subjects affected / exposed	7 / 395 (1.77%)	7 / 398 (1.76%)
occurrences (all)	9	8
Musculoskeletal/Soft Tissue - Other (Specify, __)		
alternative dictionary used: NCI 3		
subjects affected / exposed	15 / 395 (3.80%)	17 / 398 (4.27%)
occurrences (all)	17	26
Myositis (inflammation/damage of muscle)		
alternative dictionary used: NCI 3		
subjects affected / exposed	0 / 395 (0.00%)	1 / 398 (0.25%)
occurrences (all)	0	1
Osteoporosis		
alternative dictionary used: NCI 3		
subjects affected / exposed	8 / 395 (2.03%)	9 / 398 (2.26%)
occurrences (all)	8	9
Seroma		
alternative dictionary used: NCI 3		
subjects affected / exposed	1 / 395 (0.25%)	1 / 398 (0.25%)
occurrences (all)	1	1
Soft tissue necrosis - Thorax		

alternative dictionary used: NCI 3			
subjects affected / exposed	1 / 395 (0.25%)	0 / 398 (0.00%)	
occurrences (all)	1	0	
Pain - Back			
alternative dictionary used: NCI 3			
subjects affected / exposed	31 / 395 (7.85%)	32 / 398 (8.04%)	
occurrences (all)	34	41	
Pain - Bone			
alternative dictionary used: NCI 3			
subjects affected / exposed	141 / 395 (35.70%)	120 / 398 (30.15%)	
occurrences (all)	204	159	
Pain - Extremity-limb			
alternative dictionary used: NCI 3			
subjects affected / exposed	35 / 395 (8.86%)	31 / 398 (7.79%)	
occurrences (all)	43	37	
Pain - Muscle			
alternative dictionary used: NCI 3			
subjects affected / exposed	62 / 395 (15.70%)	53 / 398 (13.32%)	
occurrences (all)	82	73	
Pain - Neck			
alternative dictionary used: NCI 3			
subjects affected / exposed	5 / 395 (1.27%)	4 / 398 (1.01%)	
occurrences (all)	5	4	
Pain - Pelvis			
alternative dictionary used: NCI 3			
subjects affected / exposed	2 / 395 (0.51%)	3 / 398 (0.75%)	
occurrences (all)	2	3	
Infections and infestations			
Colitis, infectious (e.g., Clostridium difficile)			
alternative dictionary used: NCI 3			
subjects affected / exposed	2 / 395 (0.51%)	0 / 398 (0.00%)	
occurrences (all)	2	0	
Febrile neutropenia			
alternative dictionary used: NCI 3			
subjects affected / exposed	22 / 395 (5.57%)	17 / 398 (4.27%)	
occurrences (all)	22	18	

Infection - Other (Specify, __) alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	43 / 395 (10.89%) 58	59 / 398 (14.82%) 77	
Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	6 / 395 (1.52%) 6	6 / 398 (1.51%) 7	
Infection with normal ANC or Grade 1 or 2 neutrophils alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	32 / 395 (8.10%) 44	39 / 398 (9.80%) 46	
Infection with unknown ANC alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	34 / 395 (8.61%) 40	35 / 398 (8.79%) 46	
Viral hepatitis alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	0 / 395 (0.00%) 0	1 / 398 (0.25%) 1	
Metabolism and nutrition disorders Albumin, serum-low (hypoalbuminemia) alternative dictionary used: NCI 3 subjects affected / exposed occurrences (all)	3 / 395 (0.76%) 3	1 / 398 (0.25%) 1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported